Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 14, 2007

Advanced Life Sciences’ Prophylactic for Inhaled Anthrax Granted Orphan Drug Designation

  • Advanced Life Sciences Holdings’ cethromycin received Orphan Drug Designation for the prophylactic treatment of patients exposed to inhalation anthrax. “This designation will benefit us as we continue to build the cethromycin safety and efficacy database and will ultimately help position cethromycin as a potentially important antibiotic for the U.S. government's Strategic National Stockpile," says Michael T. Flavin, Ph.D., chairman and CEO.

    The company’s cethromycin is a second-generation ketolide antibiotic. Cethromycin seems to have significant in vitro activity against over 30 anthrax (Bacillus anthracis) strains. Although it is still being tested in nonhuman primates to determine its potential efficacy as an inhalation anthrax prophylactic therapy, it is in late-stage evaluations for other indications. Cethromycin is in Phase III development for the treatment of respiratory tract infections and in pivotal Phase III trials for the treatment of mild-to-moderate community acquired pneumonia.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »